
Semaglutide’s Potential to Reduce Cancer Risk in Obese American Males: A Review
Reading Time: 2 minutes Introduction Obesity is a significant public health concern in the United States, particularly among American males, where it is associated with an increased risk of various chronic diseases, including cancer. Recent research has begun to explore the potential protective effects of semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist primarily used for the management of type 2 diabetes and obesity, on cancer risk. This article delves into the current understanding of semaglutide's role in potentially mitigating cancer risk in American males with obesity. Understanding Semaglutide and Its Mechanism Semaglutide is a medication that mimics the function of the naturally occurring hormone...